Ainos, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023; filed March 8, 2024. This is an annual report, and the supplied filing text does not provide separate fourth-quarter results. Ainos is a development-stage healthcare company focused on VELDONA therapeutics and pet supplements, VOC-based point-of-care tests using its AI Nose platform, and synthetic RNA. Shares trade on Nasdaq under AIMD; warrants trade under AIMDW.
Financial performance and position
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $122,112 | $3,519,627 |
| Gross profit (loss) | $(253,733) | $1,405,343 |
| Operating expenses | $12,952,663 | $15,381,555 |
| Operating loss | $(13,206,396) | $(13,976,212) |
| Net loss | $(13,770,549) | $(14,006,690) |
| Net loss per share, basic and diluted | $(3.36) | $(5.14) |
| Net cash used in operating activities | $(4,694,668) | $(3,040,737) |
| Cash and cash equivalents at year-end | $1,885,628 | $1,853,362 |
- Revenue fell 97%, primarily as COVID-19 antigen test sales declined with the slowdown in infections in Taiwan. The filing says COVID-19 kit sales ended in January 2024. VELDONA Pet sales began in 2023 but had not generated material revenue by year-end.
- Gross margin turned negative, reflecting lower sales volumes and prices and a $235,047 inventory write-down. The filing also reports $286,777 of impairment on COVID-19 POCT-related equipment.
- Research and development expense rose 7% to $7.32 million; selling, general and administrative expense fell 34% to $5.64 million. Lower share-based compensation helped reduce the net loss slightly.
- Cash from financing activities was $4,923,673; investing activities used $101,525. Operating cash use increased year over year.
- At year-end, current assets were $2,473,197 and current liabilities were $1,336,838. Total liabilities were $7,394,223 and stockholders’ equity was $24,447,581. The balance sheet reports $5,963,556 of notes, including a Lind note carried at fair value.
- The Lind note had $3.24 million of remaining principal at year-end, despite a $2,651,556 fair-value carrying amount. It is senior secured by substantially all company assets, subject to exceptions. Other debt included $3 million of March 2025 convertible notes bearing 6% annual interest, including $2 million from a related party.
Material changes and unusual items
- In September and December 2023, Ainos drew $3 million under a Lind financing agreement for up to $10 million. The note is convertible at the lower of the stated price or a formula tied to the stock price. A $525,643 issuance cost was expensed under the fair-value accounting election; a $94,207 fair-value gain was recorded.
- Ainos issued 600,000 shares as a special stock bonus, recording $1,947,000 of expense. It also recorded $1,114,767 of share-based compensation in 2023, compared with $6,421,879 in 2022.
- A 1-for-5 reverse stock split took effect December 14, 2023. The filing retroactively adjusts share and per-share data for the split.
- In January 2024, Ainos drew additional Lind financing of up to $1.75 million, with a second installment conditional on specified requirements. After the report date, Lind converted $1,312,000 of note principal into shares. The filing also describes additional warrants and a possible maturity extension.
- In January 2024, Ainos agreed to pay controlling affiliate TCNT a monthly $95,000 patent-use fee, plus tax, for six months, and prepaid $162,840 under a five-year product-development addendum. The company reported that $285,000 of patent fees had been paid as of the report date.
- The company reported no impairment of its acquired intangible assets after a fourth-quarter recoverability analysis, but that analysis relied on assumptions about future commercialization timing, pricing, sales volume, and development costs.
Business outlook, risks, and contingencies
- Management’s near-term priorities are VELDONA Pet sales and marketing, clinical development of Ainos Flora and human VELDONA candidates, and co-development of a VOC sensing platform with Nisshinbo Micro Devices and Taiwan Inabata. Ainos Flora is in clinical study in Taiwan; the company is exploring commercialization partners.
- Management expects continued losses and negative operating cash flow while it advances products. It expects to rely on existing cash, product revenue, and additional financing, but does not assure that financing will be available on acceptable terms or when needed.
- The auditor highlighted substantial doubt about Ainos’ ability to continue as a going concern for at least one year after issuance of the financial statements. The company had a $37.9 million accumulated deficit and expects additional losses and negative operating cash flows.
- Key risks include limited revenue following the end of COVID-19 kit sales; dependence on additional capital and potential shareholder dilution; uncertain clinical outcomes and regulatory approvals; competition in pet supplements and POCT; reliance on third-party manufacturing, including controlling affiliate TCNT; and intellectual-property, privacy, reimbursement, and cybersecurity risks.
- VELDONA human candidates remain subject to clinical and regulatory development. The filing reports FDA Orphan Drug Designation for VELDONA as a potential treatment for oral warts in HIV-seropositive patients; the designation is not marketing approval.
- Ainos reported no legal proceedings, no off-balance-sheet arrangements, and no material cybersecurity incident during 2023. It reported no material impairment of intangible assets in 2023.
- Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2023. The auditor did not express an opinion on internal-control effectiveness.
Important facts for investors to verify
- Cash runway, operating cash burn, and the availability and conditions of additional Lind or other financing.
- Conversion terms, outstanding principal, collateral, warrants, and potential dilution from debt and equity awards.
- VELDONA Pet sales, return rights, distribution economics, and whether revenue can replace discontinued COVID-19 kit sales.
- Clinical-study progress and regulatory requirements for Ainos Flora and VELDONA candidates, including the status of any planned FDA discussions.
- Dependence on TCNT and other related parties, including the economics and continuation of patent-use and development agreements.
- Assumptions supporting the intangible-asset recoverability assessment and the significant future amortization expense disclosed in the filing.